Immunogenomics of Hypermutated Glioblastoma: a Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy (original) (raw)
Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape
cecile Maire
Acta Neuropathologica Communications
View PDFchevron_right
Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
Roula Farah
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016
View PDFchevron_right
TMIC-26. Immunomodulation with Temozolomide to Improve Efficacy of Immune Checkpoint Inhibition for the Treatment of Glioblastoma
Farhad Dastmalchi
Neuro-Oncology, 2017
View PDFchevron_right
Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma
ismail Saygın
Turkish Journal of Medical Sciences, 2021
View PDFchevron_right
Detection of temozolomide-induced hypermutation and response to PD-1 checkpoint inhibitor in recurrent glioblastoma
Janusz Rak
Neuro-Oncology Advances
View PDFchevron_right
Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes
cecile Maire
Clinical Cancer Research
View PDFchevron_right
Tumor Mutation Burden, Expressed Neoantigens and the Immune Microenvironment in Diffuse Gliomas
Olga Kim
Cancers, 2021
View PDFchevron_right
Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine
Connor Liu
Neuro-Oncology, 2020
View PDFchevron_right
Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma
Louis Boon
Oncoimmunology, 2017
View PDFchevron_right
Tumoral and immune heterogeneity in an anti-PD-1 responsive glioblastoma: a case study
Ilaria Laface
Molecular Case Studies
View PDFchevron_right
Predictive markers of immune response in glioblastoma: hopes and facts
Stefania Bartolini
Future Oncology, 2020
View PDFchevron_right
Biomarkers for immunotherapy for treatment of glioblastoma
Kwadwo Sarpong
Journal for ImmunoTherapy of Cancer
View PDFchevron_right
Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy
Siyi Wanggou
Frontiers in Immunology, 2022
View PDFchevron_right
Analysis of Histomorphological/molecular Association and Immune Checkpoint Regulators in Epithelioid Glioblastoma and Pleomorphic Xanthoastrocytoma: Are These Tumors Potential Candidate for Immune Checkpoint Blockade
Arvind Ahuja
2021
View PDFchevron_right
Checkpoint inhibitor failure in hypermutated and mismatch repair-mutated recurrent high-grade gliomas
Haroon Ahmad
Neuro-Oncology Practice, 2019
View PDFchevron_right
Immune check-point in glioblastoma multiforme
Francesca De Felice
Critical Reviews in Oncology Hematology, 2019
View PDFchevron_right
Molecular portrait of a rare case of metastatic glioblastoma: somatic and germline mutations using whole-exome sequencing
Angelo Giovanni Bonadio
Neuro-Oncology, 2016
View PDFchevron_right
Genetic and Immune Changes Associated with Disease Progression under the Pressure of Oncolytic Therapy in A Neuroblastoma Outlier Patient
Gustavo Melen
Cancers
View PDFchevron_right
A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma
Miguel Idoate
Biomedicines
View PDFchevron_right
Analysis of immunobiologic markers in primary and recurrent glioblastoma
Jesse Kresak
Journal of neuro-oncology, 2018
View PDFchevron_right
Glioblastoma: Pitfalls and Opportunities of Immunotherapeutic Combinations
Gabriela kramer-MareK
OncoTargets and Therapy
View PDFchevron_right
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
Hadida Yasmin
Frontiers in Immunology, 2020
View PDFchevron_right
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches
Francesca Piazzini
Journal of translational medicine, 2024
View PDFchevron_right
Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma
Agnieszka Bronisz
Neuro-Oncology, 2017
View PDFchevron_right
CBM-06 * Immune Biomarker Results from a Trial of Nivolumab Ipilimumab in Patients with Recurrent Glioblastoma: CHECKMATE-143
jason simon
Neuro-Oncology, 2015
View PDFchevron_right
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
Arpan Mahanty
Cancers, 2020
View PDFchevron_right
Blocking immunosuppressive checkpoints for glioma therapy: the more the Merrier!
Pedro Lowenstein
Clinical cancer research : an official journal of the American Association for Cancer Research, 2014
View PDFchevron_right
Low tumour-infiltrating lymphocyte density in primary and recurrent glioblastoma
Michael Fay
Oncotarget, 2021
View PDFchevron_right
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
Matteo Simonelli
Journal of Clinical Medicine, 2021
View PDFchevron_right
Current State of Immunotherapy for Treatment of Glioblastoma
Seema Nagpal
Current Treatment Options in Oncology
View PDFchevron_right
Immune genes are associated with human glioblastoma pathology and patient survival
A. Hamlat
2012
View PDFchevron_right
Immune Checkpoint Inhibitors in Gliomas
aaron tan
Current Oncology Reports, 2017
View PDFchevron_right
Deep immune profiling reveals targetable mechanisms of immune evasion in checkpoint blockade-refractory glioblastoma
Whitney Tamaki
2020
View PDFchevron_right
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
Elisa Izquierdo
Cancer cell, 2018
View PDFchevron_right